Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc's focus on developing innovative therapeutics for untreatable eye diseases and metabolic disorders positions it favorably within a high-demand market. Statistically significant results from the Phase 3 DRAGON trial demonstrate a 36% reduction in lesion growth, reinforcing the potential therapeutic efficacy of emixustat and highlighting the need for treatments in orphan indications lacking approved therapies. Additionally, the expansion of the safety database for tinlarebant in older patients could facilitate a broader label for STGD1, further enhancing the company’s growth prospects.

Bears say

Belite Bio Inc faces multiple challenges that underpin a negative outlook on its stock, particularly in relation to clinical trial outcomes and revenue projections. The company’s reliance on the successful commercialization of tinlarebant is questionable, especially given the potential necessity for substantial price reductions due to market dynamics and the expiration of relevant patents. Furthermore, despite significant projected R&D expenditures, achieving $3.1 billion in revenue post-2040 appears implausible, exacerbated by uncertainties regarding regulatory approval and market viability.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $198, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $198, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.